Meet Our Partners
Finding a treatment or cure is a TEAM approach. We are not in this alone and there is strength in numbers. Cure CMD has actively pursued partnerships with other organizations to help drive momentum, share strategies and resources. Partnership may come in the form of co-funding a research grant, co-sponsoring annual infrastructure costs, such as the CMDIR, and co-hosting Webinars to provide the community with information on care and management. Cure CMD embraces partnership as key to meeting our mission: finding a treatment and cure for the CMDs and related limb girdle spectrum disorders.
The French Muscular Dystrophy Association (AFM-Téléthon) is composed of patients and their families who are affected by a genetic, rare, progressive and severely disabling illness: neuromuscular diseases. In order to fight those diseases, AFM-Téléthon chose to initiate innovative actions and a strategy of general interest that benefits all rare diseases and all persons with disabilities.
CMDTR is a Turkish nonprofit organization founded to support the diagnosis and drug development for congenital muscular dystrophy, both domestically and internationally.
Cure LGMD2I a 501(c)(3) approved tax exempt public charity supporting research toward treatments for FKRP-Related CMD. Learn more at curelgmd2i.com.
A Foundation Building Strength (AFBS) is a non–profit organization dedicated to finding treatments for Nemaline Myopathy. Learn more at buildingstrength.org.
Global Genes provides hope for the more than 400 million people affected by rare disease around the globe. We fulfill our mission by helping patients find and build communities, gain access to information and resources, connect to researchers, clinicians, industry, government, and other stakeholders, share data and experiences, stand up, stand out, and become effective advocates on their own behalf.
I Stay Home For Rare™ is a campaign and fund offering immediate financial support to those in need during COVID-19. Join us in solidarity with those staying home protecting the lives of children, family members, and friends living with rare diseases. Learn more at ISHFR.org.
ImpulsaT (move on) - is a Spanish nonprofit association representing affected individuals with LAMA2-CMD, with the goal to promote and finance research lines that contribute to the development of treatments and a cure. Learn more at impulsat.org.
The Andrés Marcio Foundation is a nonprofit organization based in Spain whose mission is to find a cure for LMNA-CMD (Laminopathy). Learn more at fundacionandresmarcio.com.
Living in the Light is a patient advocacy initiative utilizing the potency of fine art photography, compelling personal narratives, & engaging film making to educate the biotech & medical community about the realities of rare diseases & the unprecedented effect they have on families & daily life. Their mission: empowering families and individuals affected by rare diseases to be seen and heard as they relay their stories and advocate for their needs. Learn more at frompatienttoperson.com.
The LGMD2I Research Fund is a non-profit foundation whose mission is to expedite the development of a treatment for Limb Girdle Muscular Dystrophy 2I (LGMD2I). Learn more at lgmd2ifund.org.
MightyMaje is a private initiative from Germany, whose task is to advance in LMNA-CMD (Laminopathy). Learn more at mightymaje.org.
Muscular Dystrophy United Kindom (MDUK)
Muscular Dystrophy UK (previously known as the Muscular Dystrophy Campaign) is the charity bringing individuals, families and professionals together to fight muscle-wasting conditions.
Founded in 1959, we have been leading the fight against muscle-wasting conditions since then.
We bring together more than 60 rare and very rare progressive muscle-weakening and wasting conditions, affecting around 70,000 children and adults in the UK.
The NOA Project was founded with a clear goal: To give children fighting Collagen VI Myopathies the gift of movement. Currently no treatment or therapy exists for Collagen VI Myopathies. Our main focus in Col6A2 PTC mutations is targeting the small percentage that carries a recessive stop mutation. We believe that a cure is possible.
Noelia Foundation is a non-profit organization based in Spain, whose goal is to promote disease awareness and support international research for COL6-CMD. Learn more at fundacionnoelia.org.
NORD, a 501(c)(3) organization, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 300 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
The RYR-1 Foundation was created to support research leading to effective treatments for RYR1 related disorders. Learn more at ryr1.org.
SAM is an Ireland-based nonprofit organization whose goal is to provide funding for research toward treatments and a cure for LAMA2-CMD. Learn more at helpsam.info.
TREAT-NMD was initially established as a EU funded ‘network of excellence’ with the remit of ‘reshaping the research environment’ in the neuromuscular field. The network has developed from its European roots to become a global organization bringing together leading specialists, patient groups and industry representatives to ensure preparedness for the trials and therapies of the future while promoting best practice today.
Team SuperHjalle Running Project was founded by the Lindblad Family of Sweden who run races throughout the year to raise funds for LMNA research. Learn more at
Team Titin is an advocacy group dedicated to supporting clinicians, researchers and families with titin related muscle and heart disorders. Learn more at titinmyopathy.com.
(CNM – Together Strong!) is a self-help association for myotubular myopathy and other centronuclear myopathies (CNM = ZNM) with a goal to connect those affected and their families, and to support each other in their daily lives. They also actively invest in research for these conditions. Learn more at znm-zusammenstark.org.